Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2024
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping around 500 points and significant losses in information technology shares, while utilities saw a rise. Uber's shares fell over 10% despite reporting strong quarterly revenue growth.
Global Market Trends: European and Asian markets mostly closed lower, reflecting a downward trend, while U.S. economic indicators showed a decrease in jobless claims and modest increases in personal income and spending.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATEC
Wall Street analysts forecast ATEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATEC is 24.55 USD with a low forecast of 19.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 14.850
Low
19.00
Averages
24.55
High
28.00
Current: 14.850
Low
19.00
Averages
24.55
High
28.00
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. The Company's Organic Innovation Machine is focused on developing new approaches that integrate with its expanding Alpha InformatiX (AIX) Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include AIX, positioners, access systems, implants and fixation systems, and biologics. Its AIX product platform comprises its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and its navigation-enabled robotics platform (Valence). It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphatec Holdings Shares Show Oversold Signal
- Oversold Indicator: Alphatec Holdings Inc (Ticker: ATEC) hit an RSI of 28.6 during Tuesday's trading, indicating an oversold condition with shares dropping to a low of $15, suggesting that recent heavy selling may be nearing exhaustion.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 59.1, ATEC's oversold status could attract bullish investors looking for buying opportunities, indicating a potential shift in market sentiment.
- Historical Performance: Over the past 52 weeks, ATEC's stock has seen a low of $8.81 and a high of $23.29, with the latest trade at $15.06, highlighting the stock's volatility and potential for recovery.
- Investor Focus: As ATEC approaches oversold territory, investors may begin to look for rebound opportunities, particularly in the current market environment, seeking potential low-entry points.
Continue Reading
Alphatec (ATEC) Shares Surge 9.5% on Strong 2026 Revenue Outlook of $890 Million
- Significant Price Surge: Alphatec's shares soared 9.5% in the last trading session to close at $17.46, with trading volume significantly exceeding normal levels, indicating strong investor confidence in the company's future prospects.
- Strong Revenue Outlook: The company projects total revenue of $890 million for 2026, reflecting approximately 17% growth compared to 2025, suggesting sustained market demand that could drive further stock price increases.
- Acquisition of New Product Line: Alphatec announced the acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt, a next-generation rhBMP-2 solution that will expand its procedural offerings and enhance its competitive position in the market.
- Optimistic Earnings Expectations: The upcoming quarterly report is expected to show earnings of $0.04 per share, representing a year-over-year increase of 117.4%, with revenues projected at $212.6 million, up 20.3% from the previous year, indicating strong profitability potential.
Continue Reading